Wiki · Profile

Tesamorelin

Egrifta · TH9507

GH SecretagogueApproved

MW: 5136g/mol
Formula: C221H366N72O67S

Tesamorelin, a growth hormone-releasing factor analogue, is classified as a therapeutic peptide and was developed for the management of HIV-associated lipodystrophy. Researchers primarily study tesamorelin for its effects on reducing excess abdominal fat in patients with this condition. Key findings from clinical studies indicate that tesamorelin administration leads to a significant reduction in visceral adipose tissue and improvements in metabolic parameters. Additionally, preclinical evidence suggests potential roles for tesamorelin in modulating growth hormone levels and influencing body composition. Current research continues to explore its broader applications and mechanisms of action, although robust clinical data outside of its approved indication remain limited.

Chemical Profile

Chemical Structure

Formula	C221H366N72O67S
Molecular Weight	5136 g/mol
CAS Number	218949-48-5
PubChem CID	16137828

Half-Life

SCSubcutaneous

~4 hours

INIntranasal

Not applicable

POOral

Poor bioavailability

Subcutaneous administration is the primary route due to its effective bioavailability.

Mechanism

Mechanism of Action

Tesamorelin acts as a growth hormone-releasing hormone (GHRH) analogue, binding to GHRH receptors on pituitary somatotrophs, which stimulates the secretion of endogenous growth hormone (GH). This increase in GH subsequently activates the insulin-like growth factor 1 (IGF-1) signaling pathway, promoting lipolysis and reducing visceral adiposity, particularly in HIV-infected patients with lipodystrophy. While the primary mechanisms are understood, the full extent of its biological processes and downstream effects remains to be completely elucidated.

Research

56 Research Publications

1,483

Total Citations

Human/RCT

2.5

Avg. Influence

2026

Latest

Sort

Filter

01Top

#01

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

HumanInfluence8.0

189

Researchers observed that tesamorelin treatment resulted in a 15.2% reduction in visceral adipose tissue and improved lipid profiles in HIV-infected patients.

2 mgsubcutaneously(human)daily for 12 months2 mgsubcutaneously(human)daily for 26 weeks2 mgsubcutaneously(human)daily for 6 months2 mgsubcutaneously(human)daily1 or 2 mgsubcutaneously(human)daily during 14 consecutive days

PubMed

02Top

#02

Cardiovascular risk and dyslipidemia among persons living with HIV: a review.

ReviewInfluence8.0

130

Researchers observed that cardiovascular risk management in HIV patients requires tailored interventions, including the potential use of tesamorelin for dyslipidemia.

PubMed

03Top

#03

Growth hormone in the aging male.

ReviewInfluence6.0

112

The review indicated that tesamorelin may improve mitochondrial function and reduce visceral fat in aging males, although evidence for improved quality of life remains limited.

PubMed

#04

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

HumanInfluence2.0

Researchers observed that tesamorelin treatment led to significant reductions in visceral fat and improvements in body image in HIV-infected patients over a 52-week period.

PubMed

#05

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Human

The study demonstrated that tesamorelin significantly reduced both visceral and liver fat in HIV-infected patients over 6 months, with notable metabolic improvements.

PubMed

#06

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

HumanInfluence5.0

The study demonstrated that tesamorelin significantly reduced visceral adipose tissue and improved body image in HIV-infected patients with abdominal fat accumulation over a 12-month period.

PubMed

#07

How to diagnose a lipodystrophy syndrome.

ReviewInfluence1.0

The review highlighted that lipodystrophy syndromes can arise from genetic or acquired causes, with tesamorelin being effective for managing metabolic syndrome in HIV patients.

PubMed

#08

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

HumanInfluence5.0

The study demonstrated that tesamorelin led to a significant reduction in hepatic fat fraction in HIV patients with non-alcoholic fatty liver disease compared to placebo.

PubMed

#09

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

HumanInfluence2.0

Researchers observed that long-term tesamorelin treatment resulted in sustained reductions in visceral adipose tissue and triglycerides in HIV patients without significant adverse effects on glucose levels.

PubMed

#10

Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation.

In Vitro

Researchers observed that the reductive diselenide-selenoester ligation method enabled the efficient synthesis of the therapeutic lipopeptide tesamorelin at low concentrations.

PubMed

Safety

Safety & Handling

Research Gaps

No randomized controlled human trials specifically evaluating the efficacy of tesamorelin in orthopaedic applications have been published. Additionally, the long-term effects of tesamorelin on musculoskeletal health and its mechanisms of action in tissue regeneration remain unclear.

Solubility

Tesamorelin is soluble in water and commonly reconstituted in bacteriostatic water for injection.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Approved by the FDA for the treatment of HIV-associated lipodystrophy. Not scheduled by the DEA.

🇦🇺AU

Data limited

🇬🇧UK

Data limited

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Publications per Year

48 total

Pricing

Price Comparison

BESTRetaOneLabsUS
30mg
$96.00
Price/mg
$3.20/mg
View
RetaOneLabsUS
20mg
$72.00
Price/mg
$3.60/mg
View
RetaOneLabsUS
10mg
$39.00
Price/mg
$3.90/mg
View
Alpha PeptidesUS
10mg
$39.99
$35.99
Price/mg
$4.00$3.60/mg
View−10% · PEPSTACK10
Nextech LabsUS
10mg
$48.75
Price/mg
$4.88/mg
View

Vendor	Amount	Price	Price/mg	Link
BESTRetaOneLabsUS	30mg	$96.00	$3.20/mg	View
RetaOneLabsUS	20mg	$72.00	$3.60/mg	View
RetaOneLabsUS	10mg	$39.00	$3.90/mg	View
Alpha PeptidesUS	10mg	$39.99$35.99	$4.00$3.60/mg	View−10% · PEPSTACK10
Nextech LabsUS	10mg	$48.75	$4.88/mg	View

Top 5 of 54 offers from 56 vendors. Prices updated daily.

See all Tesamorelin prices

Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Tesamorelin

Serum Level Visualizer

Visualize Tesamorelin serum levels over time

Mechanism

Related Peptides

Ipamorelin Sermorelin GHRP-2 CJC-1295 MK-677 Hexarelin

Track Tesamorelin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp Store Get it onGoogle Play

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer